Phase 1 study of oral epigallocatechin-3-gallate (EGCG) in IPF patients

$1,758,766R33FY2024HLNIH

Univ Of Massachusetts Med Sch Worcester, Worcester MA

Investigators

Fernando J Martinezcontact Harold A Chapman Catherine A Spino

Linked publications, trials & patents

Trial NCT06265532

View original record on NIH RePORTER →

Phase 1 study of oral epigallocatechin-3-gallate (EGCG) in IPF patients · GrantIndex